Full-Time

3DEXPERIENCE Saas PLM Administrator

Posted on 5/9/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Category
DevOps & Infrastructure (2)
,
Required Skills
PowerShell
Bash
AWS
DevOps
Linux/Unix
Requirements
  • Strong hands-on experience with 3DEXPERIENCE SaaS PLM platform and configuration management processes
  • Strong expertise in PLM Platform Administration with focus on CI/CD pipeline configuration, management, and release deployment
  • Hands-on experience with GitLab for build, test, deployment, and release pipeline management
  • Strong experience in AWS Cloud, especially provisioning and managing EC2 instances, Load Balancers, ACM and S3 buckets
  • Experience in cloud infrastructure management for development, test, validation, and production environments
  • Good working knowledge of Linux and Windows Server administration to troubleshoot software compatibility and environment issues
  • Experience in installation, configuration, and upgrade of third-party softwares
  • Experience in identifying and coordinating resolution of security vulnerabilities with internal IT teams and external vendors
  • Ability to generate license availability and usage reports from SaaS PLM systems
  • Strong understanding of Computerized System Validation (CSV)
  • Demonstrated experience in GxP documentation and compliance-driven release processes
  • Ability to ensure release and deployment activities meet GxP validation requirements
  • Experience in coordinating release activities with development, testing, infrastructure, and validation stakeholders in regulated environments
  • Strong experience in release management from planning through production deployment
  • Expertise in creating and managing Release Project Plans
  • Expertise in preparing release plans, workflows, and process drafts
  • Ability to drive release execution by collaborating with multiple stakeholders and tracking milestones, dependencies, risks, and timelines
  • Experience in aligning SLAs across development, testing, and validation teams for project execution
  • Strong stakeholder coordination and communication skills across development, testing, infrastructure, quality, validation, Dassault teams, IT teams, and vendors
  • Strong problem-solving skills for release, deployment, configuration, and environment-related issues
  • Ability to manage non-production environment access and license usage during development and validation phases
  • Experience working in regulated industries such as pharmaceuticals, life sciences, or medical devices
  • Familiarity with release governance, change control, and audit readiness processes
  • Experience in preparing dashboards, metrics, and management reports for release status and license utilization
  • Experience working with external vendors and enterprise IT teams for incident resolution and remediation
  • Experience with scripting and automation tools (e.g., PowerShell, Bash)
  • 3DEXPERIENCE Collaborative Business & Industry Innovator – Professional
  • SAFe Practitioner
Responsibilities
  • Configure, manage, and optimize CI/CD pipelines for the 3DEXPERIENCE SaaS PLM platform within a SaaS environment using several tools and techniques
  • Ensure CI/CD pipelines are aligned with PLM release schedules, configuration management processes, and project delivery requirements.
  • Finalize PLM release pipelines and create comprehensive Release Project Plans in Smartsheet to track milestones, dependencies, risks, and deployment timelines.
  • Drive end-to-end PLM release activities from planning through production deployment, ensuring timely execution and coordination across all stakeholders.
  • Collaborate with business, development, testing, validation, infrastructure, and Dassault teams to ensure GxP validation requirements are met throughout the release lifecycle.
  • Develop and maintain PLM release plans, process flows, and deployment roadmaps in Miro for clear cross-functional visibility and execution tracking.
  • Coordinate with PLM development and testing teams to define and align SLAs for each activity, as applicable to the GxP validation process.
  • Set up and maintain PLM infrastructure for automated code builds, testing, and deployments across development, test, and production environments.
  • Provision AWS cloud infrastructure, including EC2 instances and S3 buckets, based on project and environment requirements.
  • Manage installation, configuration, and upgrade of third-party software components required for project delivery and platform support.
  • Resolve PLM deployment, configuration, and environment issues by working closely with internal IT teams, Dassault teams, and external vendors.
  • Identify, track, and remediate PLM infrastructure and application vulnerabilities in collaboration with multiple IT teams and external service providers.
  • Manage access control and license utilization for PLM non-production environments during development and validation phases.
  • Generate on-demand reports on SaaS PLM license availability and usage to support planning, governance, and operational decision-making.
  • Apply knowledge of Linux and Windows Server administration to troubleshoot software compatibility, environment stability, and deployment-related issues.
  • Support computerized system validation activities with strong understanding of CSV, GxP documentation, and compliance requirements.
  • Ensure all PLM release and deployment activities are properly documented and executed in accordance with quality, compliance, and organizational standards.
Desired Qualifications
  • Experience working in regulated industries such as pharmaceuticals, life sciences, or medical devices
  • Familiarity with release governance, change control, and audit readiness processes
  • Experience in preparing dashboards, metrics, and management reports for release status and license utilization
  • Experience working with external vendors and enterprise IT teams for incident resolution and remediation
  • Experience with scripting and automation tools (e.g., PowerShell, Bash)
  • Strong analytical and troubleshooting skills
  • Excellent analytical and troubleshooting skills
  • Strong verbal and written communication skills
  • Ability to work effectively with global, virtual teams
  • High degree of initiative and self-motivation
  • Ability to manage multiple priorities successfully
  • Team-oriented, with a focus on achieving team goals
  • Strong presentation and public speaking skills

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.